The Acute Myeloid Leukemia variant DNMT3A Arg882His is a DNMT3B-like enzyme
Mutations in DNMT3A, particularly the Arg882His substitution is highly prevalent in acute myeloid leukemia. Although the reduced activity of DNMT3A Arg882His variant alters DNA methylation, the underlying cause of its oncogenic effect is not fully understood. Our data show that DNMT3A Arg882His variant acquires CpG flanking sequence preference highly similar to that of DNMT3B. Interestingly, a similar substrate preference was observed in DNMT3A WT enzyme upon the loss of cooperative kinetic mechanism. We tested if DNMT3A Arg882His could preferably methylate DNMT3B-specific target sites. Rescue experiments in Dnmt3a/3b double knockout mouse embryonic stem cells show that the corresponding Arg878His mutation in mouse DNMT3A severely impairs its ability to methylate major satellite DNA, a DNMT3A-preferred target, but has no overt effect on the ability to methylate minor satellite DNA, a DNMT3B-preferred target. Our data suggest that methylation of DNMT3B target sites by DNMT3A Arg882His variant could contribute to its oncogenic potential.